The AstraZeneca/Oxford University COVID-19 vaccine has up to 90% efficacy against SARS-CoV-2—and would be easier to distribute than other promising candidates, according to interim results from a Phase 3 vaccine trial.  

The antiviral remdesivir should not be used as a treatment for hospitalized COVID-19 patients, the WHO now says, citing a lack of evidence that it improves survival or reduces the need for ventilators, 

One of the first conditions to be screened for in utero and one of the least severe, Down syndrome is regarded as the “canary in the coal mine” for selective reproduction.   In Denmark, where universal Down syndrome screening is available, nearly all families get the test…

A startling statistic: “If the health sector globally were a country, it would be the fifth [largest] emitter of greenhouse gases,” says Susan Wilburn of Care Without Harm.  

One of the biggest challenges of distributing a COVID-19 vaccine: cold storage—and one of the most promising vaccine candidates yet has particularly high maintenance requirements.   Pfizer’s vaccine must be kept “colder than winter in Antarctica”: -70 degrees C to be exact…

Sometimes trials are stopped early because the news is good—and this is one of those times.  

A landmark study of Ebola survivors could have big implications for COVID-19 research.  

Growing up in a rural area near Kisumu, Kenya, I never realized that malaria, one of the world’s oldest and deadliest diseases, was entirely preventable and treatable. It is a threat that my elders have never lived without—but my generation can end it.

This is good news: A cocktail of synthetic antibodies has shown promising, early results for beating back the coronavirus in patients that aren’t yet seriously ill.  

Copper is well-known as a ruthless germ killer—and a growing body of research supports its powers to slow the spread of infections in hospitals.   Could swapping stainless steel surfaces for copper be a game-changer?